Results 141 to 150 of about 82,941 (302)

Chemotherapy‐Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline‐Free Regimen With Docetaxel, Cyclophosphamide—Results From a Randomized Clinical Trial

International Journal of Cancer, EarlyView.
Chemotherapy‐induced nausea and vomiting (CINV) remains a significant clinical problem despite modern antiemetics. In particular, antiemetic strategies for emerging cancer therapies lack detailed evaluation. This randomized trial analyzed hourly CINV data for patients with early breast cancer who received either docetaxel plus cyclophosphamide (TC) or ...
Manuel Hörner, Henning Schäffler, Lothar Häberle, Chloë Goossens, Kerstin Pfister, Elena Leinert, Kristina Veselinovic, Sara Y. Brucker, Uwe Köhler, Georg Heinrich, Andreas Schneeweiss, Matthias W. Beckmann, Peter A. Fasching, Wolfgang Janni, Brigitte Rack, Sabine Heublein, Philipp Ziegler   +16 more
wiley   +1 more source

Programmed Cell Death Ligand 1 (PD-L1) and major Histocompatibility Complex Class I (MHC Class I) Expression Patterns and Their Pathologic Associations in triple-Negative Breast Cancer

Breast Cancer: Targets and Therapy
Ponkrit Kaewkedsri,1 Piyapharom Intarawichian,1 Sirawich Jessadapattarakul,1 Waritta Kunprom,1 Supinda Koonmee,1 Malinee Thanee,1 Ongart Somintara,2 Anongporn Wongbuddha,2 Payia Chadbunchachai,3 Supajit Nawapun,3 Chaiwat Aphivatanasiri1 1Department of ...
Kaewkedsri P, Intarawichian P, Jessadapattarakul S, Kunprom W, Koonmee S, Thanee M, Somintara O, Wongbuddha A, Chadbunchachai P, Nawapun S, Aphivatanasiri C   +10 more
doaj  

Multidisciplinary Strategies for Targeting Tumor Dormancy in Breast Cancer Therapeutics: Hallmarks, Mechanism, and Approaches

iMetaMed, EarlyView.
Clinical phases and classification of breast tumor dormancy. Tumor dormancy is described as the period after treatment until residual tumor cells become detectable as relapsing disease in clinic. During the period of clinical tumor dormancy, tumor mass dormancy and cellular dormancy may coexist.
Shu Chen, Hui Chen, Vijaya Raghavan, Jing Huang, Jin Wang   +4 more
wiley   +1 more source

Multiomics Analysis of Gene Expression and Drug Sensitivity Relationship in Breast Cancer Subtypes

Online Academic Journal of Information Technology
Breast cancer is a complex disease exhibiting distinct clinical behaviors due to its molecular heterogeneity. In this study, 30 breast cancer cell lines were categorized into two main analysis groups: 'Hormone/HER2 Positive' (n=12) and 'TNBC' (triple ...
Adem Sonuvar, Esra Tokur Sonuvar, Uğur Bilge   +2 more
doaj   +1 more source

Black phosphorus‐based photothermal disruption of cancer‐associated fibroblast barriers and tumor‐associated macrophage targeting to enhance anti‐PD‐L1 immunotherapy in triple‐negative breast cancer

Interdisciplinary Medicine, EarlyView.
MBB modulates the TNBC tumor microenvironment by targeting TAM/CXCL1 and facilitates anti‐PD‐L1 therapy by disrupting CAF barriers via its photothermal effect. This combined strategy subsequently enhances the efficacy of PD‐L1 mAb and suppresses TNBC progression, metastasis, and recurrence.
Bo Pan, Shicui Hong, Xinyue Wang, Yanghang Li, Cai Wang, Yaxiao Liu, Ying Chen, Chen Fang, Yifeng Zheng, Shengqi Wang, Juping Zhang, Neng Wang, Zhiyu Wang   +12 more
wiley   +1 more source

Chitosan nanoparticle‐mediated delivery of anti‐miR‐203a‐3p for 4T1 triple‐negative breast cancer

Indonesian Journal of Biotechnology
Anti‐miR molecules can suppress specific microRNA (miRNA) functions within critical signaling pathways. Chitosan acts as a delivery system for miRNAs; therefore, encapsulating miR‐203a‐3p is essential for targeted delivery and biological activity.
Jecklyn Shindy Temartenan, Hairil Fiqri, Pamungkas Bagus Satriyo, Sofia Mubarika Haryana   +3 more
doaj   +1 more source

Targeting eIF5A combats breast cancer progression by ClpP‐dependent mitochondrial oxidative stress

Interdisciplinary Medicine, EarlyView.
This study identified the eIF5A‐ClpP axis as a key driver of breast cancer progression. Targeting eIF5A suppresses tumor growth by inducing ClpP‐dependent mitochondrial oxidative stress, revealing a novel therapeutic vulnerability. Abstract Breast cancer (BC) poses a persistent global health challenge, necessitating new therapeutic targets.
Jinmei Zhu, Baoyuan Tang, Bei Xie, Haohua Deng, Haitang Yang, Lei Ma, Ziqing Zhang, Yicheng Ma, Xingyuan Ma, Shuaiyang Wang, Jing Li, Lei Zhao, Wengui Shi, Linjing Li   +13 more
wiley   +1 more source

Phosphatase activation in TNBC.

Phosphatases were present both in small and large quantities, and activated in resistance. PTPRU, PTPRN, PTPRO, ENPP2, and PPP2R2C were among the phosphatases most dramatically activated. 
openaire   +2 more sources

A compendium of extracellular vesicle biogenesis inhibitors: From bench to bedside

Interdisciplinary Medicine, EarlyView.
This review explores a decade of research on extracellular vesicles (EVs), detailing their biogenesis and roles in health and disease. It emphasizes EVs' relevance for potential medical applications covering various conditions such as cancer, neurodegeneration, inflammation, and infectious diseases, bridging experimental findings with clinical ...
Stefano Vecchione, Ana Talamillo, Juan M. Falcón‐Pérez   +2 more
wiley   +1 more source

Omission of Sentinel Lymph Node Biopsy in Breast Cancer: A Real‐World Validation of the Patient Populations of the SOUND and INSEMA Trials

Journal of Surgical Oncology, EarlyView.
ABSTRACT Background Treatment guidelines recommending omission of axillary surgery in breast cancer are largely based on the SOUND and INSEMA trials. However, the extent to which their study populations represent real‐world patients remains unclear.
Tia Puiras, Eeva Juhanoja, Anselm Tamminen   +2 more
wiley   +1 more source